

Morbidity and Mortality Working Party

Membership

Dr Mike Makris (Chairman)
Dr Gerry Dolan
Dr Jonathan Wilde
Dr Henry Watson
Dr Carolyn Millar
Dr Thynn Yee

Terms of reference

1. To monitor and advise on the management infections with HIV, HCV and vCJD in haemophilia
2. To review and monitor adverse events as reported on the orange card system
3. To monitor and advise on the management of thrombosis and cardiovascular disease in haemophilia
4. To monitor and analyse mortality data

Main Issues

variant CJD

A paper on patients exposed to batches of FVIII from donors who subsequently developed vCJD has been published in Haemophilia. The WP party reviews all the vCJD issues as they affect haemophilia at a regular basis. There have been no cases of vCJD in Haemophilia during the year.

Hepatitis C

The hepatitis C guideline published in 2001 has been revised, updated and has been accepted for publication by Haemophilia with Jonathan Wilde as the lead author. The WP is reviewing the number of liver transplants performed in haemophiliacs in the UK as well as their long term outcome.

The hepatitis C look-back is on-going.

The Skipton Fund changed their rules, especially for patients who died prior to 2003. The new applications have put pressure on haemophilia centres because a lot of the information required is not easily available.

Adverse event reporting

During the coming year the reporting system will be modified so it is all electronic and the details to be supplied when submitting an event will be greater.

Dr Mike Makris
Chairman, Morbidity and Mortality Working Party
August 2011